In the treatment of AML, R-2HG (produced by mutated isocitrate dehydrogenase 1/2 (IDH1/2) catalyzes the conversion of α-KG), an oncometabolite, inhibits the enzymatic activity of FTO and displays a significant antitumor effect in leukemia and glioma by targeting the FTO/MYC/CEBPA (CCAAT enhancer binding protein alpha) axis (59, 103, 104). Here, CEBPA is linked to central nervous system cancer.